Recently, JumpCan Pharmaceutical received the Drug Registration Certificates (Certificate No. 2024S01128 and 2024S01129) issued by the National Medical Products Administration (NMPA) for Fexofenadine Hydrochloride for Suspension in two strengths: 30mg and 15mg. This makes JumpCan Pharmaceutical the first pharmaceutical company in China to receive approval for this formulation, offering patients a better medication option. The product is indicated for relieving symptoms of seasonal allergic rhinitis and chronic idiopathic urticaria in children aged six months and older and adults. It is considered to have passed the consistency evaluation for generic drug quality and efficacy.
Fexofenadine Hydrochloride is a second-generation H1 receptor antagonist with excellent antihistamine effects. The dry suspension formulation combines the advantages of solid (granules) and liquid dosage forms—portable, stable, and easy to administer. It is particularly suitable for children and elderly patients with swallowing difficulties, helping to improve the medication experience. Precise dosing instructions are provided for each age group, supporting rational medication use. Additionally, a unique taste-masking technology significantly improves palatability.
Adhering to its corporate mission of “Using Technology to Defend Health” and the R&D philosophy of “Leading the Frontier, Innovating Fine Products”, JumpCan Pharmaceutical remains patient-centered, strengthening the development of innovative drugs and high-end specialized generics while promoting the innovative development of traditional Chinese medicine. Over the past two years, the company has invested over RMB 1 billion in R&D, with 13 new products approved for market. Among these, Magnesium Sulfate, Sodium Sulfate and Potassium Sulfate Concentrate Oral Solution (Chuanbeiqing), and 20mg Rabeprazole Sodium Enteric-coated Tablets (JumpCan Sainuo) were the first to be approved in China. Xiao'er Chiqiao Qingre Syrup (K-tonpei) is the first improved traditional Chinese medicine approved under the new Provisions for Drug Registration. These achievements continuously meet diverse patient needs, enrich the product pipeline, and inject new momentum into the company’s growth.
In recent years, JumpCan Pharmaceutical has actively established strategic partnerships with multiple multinational corporations and biotech companies to provide patients with diverse innovative treatments. Collaborating with TJ Biopharma to develop a Class 1 innovative fusion protein-based long-acting growth hormone, which has completed Phase III clinical trials; reaching a strategic collaboration with Newsoara Biopharma on two innovative drugs — an oral PDE4 (phosphodiesterase 4) inhibitor and a drug-targeted digestive protease inhibitor; and signing a cooperation agreement last year with Zenshine Pharmaceuticals to develop a Class 1 innovative drug for influenza prevention and treatment — a next-generation polymerase acidic protein (PA) endonuclease inhibitor with broad-spectrum anti-influenza virus properties, and its New Drug Application (NDA) has been accepted by the Center for Drug Evaluation (CDE) , NMPA.